| Li, Qi |
| Active, not recruiting | 4 | 1127 | RoW | Yangzheng Compound Mixture, Z10970042（NMPA Approval Number）, Conventional Treatment | ShuGuang Hospital, LinkDoc Technology (Beijing) Co. Ltd., Shaanxi Buchang Pharmaceutical Co., Ltd | Carcinoma, Sleep Disorder | 09/23 | 06/24 | | |
SELECT-2, NCT04401059: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study |
|
|
| Recruiting | 4 | 744 | RoW | Elemene plus first or third generation EGFR-TKIs, H10960114, H20010338, First or third generation EGFR-TKIs, Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc. | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma | 09/25 | 03/26 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT04674956: A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer |
|
|
| Recruiting | 3 | 401 | RoW | Camrelizumab, Paclitaxel(Albumin Bound) and Gemcitabine, Placebo | RenJi Hospital | Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic | 12/24 | 12/25 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor |
|
|
| Recruiting | 2 | 200 | RoW | TQ-B3101 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 03/21 | 09/21 | | |
| Recruiting | 2 | 69 | RoW | Regorafenib Pill&Camrelizumab | Nanfang Hospital of Southern Medical University, Jiangsu HengRui Medicine Co., Ltd. | Hepatocellular Carcinoma | 01/22 | 01/22 | | |
NCT05536102: The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) |
|
|
| Recruiting | 2 | 38 | RoW | PLD, Pegylated Liposomal Doxorubicin, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Tislelizumab, BGB-A317 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Gastric Cancer | 09/23 | 09/27 | | |
NCT06356597: Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial |
|
|
| Recruiting | 2 | 25 | RoW | Tislelizumab with Fruquintinib, Metronidazole | Jing-yuan Fang, MD, Ph. D | Colorectal Cancer | 12/25 | 12/27 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
NCT06212076: Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients |
|
|
| Not yet recruiting | 1/2 | 60 | RoW | IPG1094 | Nanjing Immunophage Biotech Co., Ltd | Solid Tumor | 07/24 | 08/24 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
NCT04606472: A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 159 | RoW | SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Solid Tumor | 06/25 | 06/25 | | |
NCT06619886: TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor |
|
|
| Not yet recruiting | 1 | 9 | RoW | Autologous, engineered T Cells targeting TP53 R248Q | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Solid Tumor, Adult, Lung Adenocarcinoma, Pancreas Cancer, Colorectal Cancer, Other Solid Tumor | 10/26 | 10/27 | | |
| Recruiting | 1 | 12 | RoW | SN301A, Fludarabine, Cyclophosphamide | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Celest Therapeutics Co. Ltd, Senti Biosciences | Hepatocellular Carcinoma (HCC) | 10/26 | 10/27 | | |
| Recruiting | 1 | 48 | RoW | SM3321 | Beijing StarMab Biomed Technology Ltd | Locally Advanced or Metastatic Solid Tumors | 08/25 | 10/25 | | |
| Recruiting | N/A | 1000 | RoW | | First Affiliated Hospital of Chongqing Medical University | Intracerebral Hemorrhage, Stroke, Hematoma | 02/19 | 01/23 | | |
SELECT-1, NCT04397432: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study |
|
|
| Active, not recruiting | N/A | 878 | RoW | | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung | 04/23 | 03/26 | | |
IIT-QY-1-T, NCT06251115: Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC |
|
|
| Recruiting | N/A | 9 | RoW | QY-1-T | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shenzhen Zhongke Qiyuan Biotechnology Co., Ltd. | Liver Cancer | 01/25 | 10/25 | | |
ABOARD, NCT06635993: Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion |
|
|
| Recruiting | N/A | 97 | RoW | 68Ga-Pentixafor PET/CT | Qifu Li, The First Affiliated Hospital of Zhengzhou University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Third Xiangya Hospital of Central South University, The Affiliated Hospital Of Southwest Medical University | Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion | 08/26 | 08/27 | | |
| Wang, Ziping |
SELECT-2, NCT04401059: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study |
|
|
| Recruiting | 4 | 744 | RoW | Elemene plus first or third generation EGFR-TKIs, H10960114, H20010338, First or third generation EGFR-TKIs, Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc. | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma | 09/25 | 03/26 | | |
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC |
|
|
| Withdrawn | 2 | 80 | Europe, RoW | YH001 + Toripalimab | Eucure (Beijing) Biopharma Co., Ltd | HCC, NSCLC Stage IIIB, NSCLC Stage IV | 12/24 | 03/25 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
NCT04956926: Clinical Study of JS201 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 244 | RoW | JS201 | Shanghai Junshi Bioscience Co., Ltd. | Patients With Advanced Malignant Tumors | 07/23 | 07/23 | | |
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients with Advanced Solid Tumours |
|
|
| Active, not recruiting | 1 | 81 | RoW | RC88, The injectable RC88 | RemeGen Co., Ltd. | Advanced Solid Tumours | 06/25 | 12/25 | | |
NCT02929290: Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC |
|
|
| Recruiting | 1 | 80 | RoW | BPI-9016M, No other name so far | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
SELECT-1, NCT04397432: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study |
|
|
| Active, not recruiting | N/A | 878 | RoW | | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung | 04/23 | 03/26 | | |
| Wei, Bing |
SELECT-2, NCT04401059: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study |
|
|
| Recruiting | 4 | 744 | RoW | Elemene plus first or third generation EGFR-TKIs, H10960114, H20010338, First or third generation EGFR-TKIs, Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc. | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma | 09/25 | 03/26 | | |
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer |
|
|
| Recruiting | 3 | 35 | RoW | Mirvetuximab Soravtansine, IMGN853, MIRV | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 04/23 | 12/23 | | |
SELECT-1, NCT04397432: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study |
|
|
| Active, not recruiting | N/A | 878 | RoW | | Tian Xie, LinkDoc Technology (Beijing) Co. Ltd. | Carcinoma, Non-Small-Cell Lung | 04/23 | 03/26 | | |
